entertainment -WSS

entertainment

author：focus 2025-10-01 23:00:36 - browse：99695

Johnson & Johnson sign — MARK RALSTON/AFP via Getty Images

WASHINGTON — Pharmaceutical giant Johnson & Johnson on Tuesday became the third drugmaker to sue the Biden administration over its new Medicare drug price negotiation program.

J&J joins a flurry of litigation challenging the Medicare drug price negotiation program, which is set to start this fall. Merck, Bristol Myers Squibb, the brand-drug lobby PhRMA, and the U.S. Chamber of Commerce have also filed suit. The negotiated prices would go into effect in 2026.

The company argued that it is entitled to sue because its blockbuster blood thinner drug Xarelto may be up for negotiation in the first round of ten drugs Medicare will examine, but that list is not set to be announced officially until Sept. 1.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Can Threads overtake X, formerly known as Twitter? Experts weigh in.

explore

Wikipedia

WSS

Carvykti CAR

Ohioans vote in high

Grail spinoff by Illumina should end disastrous merger attempt

Virtual care provider acquires bankrupt Pear's prescription apps

Choosing scientific sides in the fight against Alzheimer's

The painfully weak evidence on taking collagen to treat arthritis

entertainment

entertainment

knowledge

Activists slam private health insurers over coverage restrictions

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Medicare proposal to cover medical devices draws a mixed reaction

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

BioMarin wins approval for gene therapy to treat hemophilia A

Germany receives 178 compensation applications from gay servicepeople over discrimination

Supreme Court strikes down use of affirmative action

Biden praises World Series champion Astros for impact off the field during White House celebration

Peter Hotez and the public health issue of online harassment

Why health records don't always know when patients are dead

leisure time

Prime Medicine, Myeloid Therapeutics clash over genome

Keeping primary care docs in field isn't impossible, says AAFP CEO

Hospitals owned by private equity see complications spike 25%

Choosing scientific sides in the fight against Alzheimer's

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Why health records don't always know when patients are dead

explore

Wikipedia

leisure time

Wikipedia